Recent discussions on X about Larimar Therapeutics (LRMR) have centered on the company's announcement of a proposed underwritten public offering, which caught many investors by surprise. The offering, priced at $3.20 per share, has sparked debates about the timing, especially with key data releases expected in September. Some users on the platform expressed concern over the immediate stock price drop following the news, though others noted a quick recovery in share value.
Further fueling the conversation is the speculation around the motives behind the offering, with some suggesting it could indicate strong interest from institutional investors or funds looking to increase their stakes. The price action post-announcement has been described as intriguing, with a mix of frustration and curiosity circulating among participants. This development has kept LRMR a focal point for biotech stock watchers on social media.
Note: This discussion summary was generated from an AI condensation of post data.
Larimar Therapeutics Insider Trading Activity
Larimar Therapeutics insiders have traded $LRMR stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LRMR stock by insiders over the last 6 months:
- JAMES E FLYNN has made 3 purchases buying 9,375,000 shares for an estimated $30,000,000 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Larimar Therapeutics Hedge Fund Activity
We have seen 54 institutional investors add shares of Larimar Therapeutics stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,100,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,515,000
- OPALEYE MANAGEMENT INC. added 1,914,077 shares (+inf%) to their portfolio in Q1 2025, for an estimated $4,115,265
- GOLDMAN SACHS GROUP INC removed 1,480,957 shares (-35.7%) from their portfolio in Q1 2025, for an estimated $3,184,057
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 913,861 shares (-72.0%) from their portfolio in Q1 2025, for an estimated $1,964,801
- JANUS HENDERSON GROUP PLC removed 871,323 shares (-13.5%) from their portfolio in Q1 2025, for an estimated $1,873,344
- FRED ALGER MANAGEMENT, LLC removed 737,553 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,585,738
- RENAISSANCE TECHNOLOGIES LLC added 461,429 shares (+89.9%) to their portfolio in Q1 2025, for an estimated $992,072
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Larimar Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $LRMR in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 06/25/2025
- Wedbush issued a "Outperform" rating on 06/24/2025
- Baird issued a "Outperform" rating on 03/25/2025
- HC Wainwright & Co. issued a "Buy" rating on 03/25/2025
To track analyst ratings and price targets for Larimar Therapeutics, check out Quiver Quantitative's $LRMR forecast page.
Larimar Therapeutics Price Targets
Multiple analysts have issued price targets for $LRMR recently. We have seen 4 analysts offer price targets for $LRMR in the last 6 months, with a median target of $15.5.
Here are some recent targets:
- Yatin Suneja from Guggenheim set a target price of $26.0 on 06/25/2025
- Laura Chico from Wedbush set a target price of $15.0 on 06/24/2025
- Joel Beatty from Baird set a target price of $10.0 on 03/25/2025
- Edward White from HC Wainwright & Co. set a target price of $16.0 on 03/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
